GlobalResearch
Center for Research on Globalization

Could Avian H5N1 Influenza be Disease X for the Bio-Pharmaceutical Complex?

Fear Mongering, Food Supply Threat, Virus with a Deadly Past, BARDA Self-Amplifying mRNA Vaccines--A Perfect Storm is Brewing

By Dr. Peter McCullough and Nicolas Hulscher
Global Research, April 10, 2024
Courageous Discourse
Theme: Science and Medicine

***

With the fear-mongering campaign of 'Disease X' sponsored by the Coalition for Epidemic Preparedness and Innovation (CEPI), people are wondering what virus might infect the world next. A few days ago, the CDC issued a health advisory for the H5N1 bird flu as it was detected in a Texas dairy farm worker [1]. His only symptom was conjunctivitis, or inflammation of the eye. As of today, human-to-human transmission has not occurred and thus H5N1 poses limited risk to humans. However, this may change in the near future, especially if we consider the dark history of gain of function (GOF) research regarding H5N1.

Highly Pathogenic Avian Influenza A(H5N1) Virus: Identification of Human Infection and Recommendations for Investigations and Response

Print

Distributed via the CDC Health Alert Network
April 05, 2024, 01:30 PM ET
CDCHAN-00506

Summary
The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to inform clinicians, state health departments, and the public of a recently confirmed human infection with highly pathogenic avian influenza (HPAI) A(H5N1) virus in the United States following exposure to presumably infected dairy cattle. The U.S. Department of Agriculture (USDA) recently reported detections of highly pathogenic avian influenza A(H5N1) virus in U.S. dairy cattle in multiple states. This Health Advisory also includes a summary of interim CDC recommendations for preventing, monitoring, and conducting public health investigations of potential human infections with HPAI A(H5N1) virus.

Over a decade ago, the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation funded GOF research that made H5N1 more transmissible [2]. One of the primary authors of this dangerous research is Yoshihiro Kawaoka, who is affiliated with the University of Wisconsin-Madison and University of Tokyo. Another player is Ron Fouchier, working at the Erasmus medical center in the Netherlands [2]. These two have a deep history of modifying viruses in laboratories and infecting animals with various types of pathogens. This research prompted a short pause on GOF research funding by the US government to assess risks [3]. A few years later, in 2017, the NIH resumed funding GOF research [4] because the HHS P3CO Framework was released, detailing ‘safe’ methods to conduct dangerous research with modified pathogens [5]. Charostad, et al, in 2023 indicated that highly pathogenic avian influenza (H5N1) is an “imminent threat.”

Review > Travel Med Infect Dis. 2023 Sep-Oct:55:102638. doi: 10.1016/j.tmaid.2023.102638. Epub 2023 Aug 30.

A comprehensive review of highly pathogenic avian influenza (HPAI) H5N1: An imminent threat at doorstep

Javad Charostad [1], Mohammad Rezaei Zadeh Rukerd [2], Shahab Mahmoudvand [3], Davood Bashash [4], Seyed Mohammad Ali Hashemi [5], Mohsen Nakhaie [6], Keivan Zandi [7]

Affiliations + expand

PMID: 37652253 DOI: 10.1016/j.tmaid.2023.102638

Free article

Abstract

Avian influenza viruses (AIVs) are globally challenging due to widespread circulation and high mortality rates. Highly pathogenic avian influenza (HPAI) strains like H5N1 have caused significant outbreaks in birds. Since 2003 to 14 July 2023, the World Health Organization (WHO) has documented 878 cases of HPAI H5N1 infection in humans and 458 (52.16%) fatalities in 23 countries. Recent outbreaks in wild birds, domestic birds, sea lions, minks, and etc., and the occurrence of genetic variations among HPAI H5N1 strains raise concerns about potential transmission and public health risks. This paper aims to provide a comprehensive overview of the current understanding and new insights into HPAI H5N1. It begins with an introduction to the significance of studying this virus and highlighting the need for updated knowledge. The origin and evaluation of HPAI H5N1 are examined, shedding light on its emergence, and spread across different geographic regions. The genome organization and structural biology of the H5N1 virus are explored, providing insights into its molecular composition and key structural features. This manuscript also delves into the phylogeny, evolution, mutational trends, reservoirs, and transmission routes of HPAI H5N1. The immune response against HPAI H5N1 and its implications for vaccine development are analyzed, along with an exploration of the pathogenesis and clinical manifestations of HPAI H5N1 in human cases. Furthermore, diagnostic tools and preventive and therapeutic strategies are discussed, highlighting the current approaches and potential future directions for better management of the potential pandemic.

Keywords: Avian influenza; Genetic variations; H5N1; Highly pathogenic avian influenza; Surveillance.

With this pretext in 2020, the FDA approved the first H5N1 vaccine, *Audenz*, for ages 6 months and older [6]. This vaccine was developed by CSL Seqirus, a company funded by the Biomedical Advanced Research and Development Authority (BARDA) [7]. The first generation product comes from a cell-based, combination inactive antigen platform. The second generation is planned to be self-amplifying mRNA (sa-mRNA) technology. Perhaps there's a reason the US government is already stockpiling an 'approved' vaccine for a virus that doesn't spread in humans. The CDC alert does not mention the approved vaccine, saying that they will develop one if needed. Very strange.

CSL Seqirus

Global Selector | News | Partnering | Contact

Our Company | Expertise | Products | Careers

Summit, NJ, USA | 23 Nov 2021

CSL Seqirus > News > Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

The FDA approval of the MDV presentation[2] of AUDENZ™, which was originally approved by the FDA in 2020 in a single dose, prefilled syringe (PFS) presentation, marks an important milestone in Seqirus' pandemic preparedness efforts in partnership with Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under the terms of the public-private partnership, established in 2009, Seqirus would position itself to deliver 150 million influenza vaccine doses to the U.S. government to support an influenza pandemic response within six months.[3,4]

"Producing AUDENZ in multi-dose vials allows for increased speed and efficiency, which is absolutely critical to help protect public health in the case of an influenza pandemic," said Marc Lacey, Executive Director, Pandemic Response Solutions, Seqirus. "According to the CDC, the influenza A(H5N1) virus is highly pathogenic and has high pandemic potential, so it's critical to be prepared. Seqirus is committed to partnering with key stakeholders to develop adequate and effective influenza pandemic preparedness plans."

Longstanding Partnership Between Seqirus and BARDA

Seqirus' longstanding partnership with BARDA also supported the company's cell-based manufacturing facility in Holly Springs, N.C., the first such domestic facility, that utilizes a highly scalable method of production.

In October 2021, Seqirus announced a new $34.95 million agreement with BARDA to develop two influenza A(H2Nx) virus vaccine candidates: the first using the adjuvanted, cell-based combination platform technology used by AUDENZ™, and the second using Seqirus' next-generation self-amplifying mRNA (sa-mRNA) platform.

ADVERSE REACTIONS

- In adults 18 through 64 years of age, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were injection site pain (64%), fatigue (25%), headache (25%), malaise (22%), myalgia (14%), arthralgia (10%), and nausea (10%).
- In adults 65 years of age and older, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were injection site pain (36%), fatigue (20%), malaise (16%), headache (16%), and arthralgia (10%).
- In infants and children, 6 months through 5 years of age, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were tenderness (56%), irritability (30%), sleepiness (25%), change in eating habits (18%), and fever (16%).
- In children 6 through 17 years of age, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were injection site pain (68%), myalgia (30%), fatigue (27%), malaise (25%), headache (22%), loss of appetite (14%), nausea (13%), and arthralgia (13%).

CEPI is similarly funding Korea's Chungbuk National University (CBNU) to create novel sa-mRNA vaccines to combat H5N1. This new platform is basically current mRNA vaccines on steroids, with self replicating RNA causing massive amount of foreign protein.

End Pandemics News

CEPI supports novel mRNA vaccine development in Korea to protect against future Disease X

CEPI • 11th December 2023

With CEPI's support, CBNU will first assess the platform against avian influenza H5N1 virus. The findings will provide a model to help assess this new technology and explore how it could be used to rapidly respond to a future Disease X in as little as 100 days. The 100 Days Mission is an ambitious goal spearheaded by CEPI, and embraced by the Republic of Korea as part of its strategic plan against emerging infectious diseases, that aims to accelerate vaccine development to around 100 days from virus identification, potentially stopping a future outbreak in its tracks before it becomes a pandemic.

Bill Gates and the World Economic Forum (WEF) believe we should reduce our reliance on animal food products [8,9] as part of their globalist views [10]. Thus, a food scare in westernized countries with market recalls and destruction of poultry and meat would further dystopian goals for the Davos club [11]. H5N1 has a historical fatality rate of 52.16% in humans and fear alone could drive considerable anxiety in large populations not only about exposure through food, but pets, and other humans [12].

It's difficult to determine if H5N1 is the next 'Disease X' at the moment. It's possible due to the abundance of GOF research and biotech interests, ready-made vaccines, and powerful drivers of mass panic in the wings. If more cases occur in clusters or bona fide outbreaks with human-to-human transmission, we could be well on our way to a 2024 avian influenza pandemic crisis.

*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter

and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Notes

1. https://emergency.cdc.gov/han/2024/han00506.asp

2. https://www.ncbi.nlm.nih.gov/books/NBK206985/

3. https://obamawhitehouse.archives.gov/blog/2014/10/17/doing-diligence-assess-risks-and-benefits-life-sciences-gain-function-research

4. https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-lifts-funding-pause-gain-function-research

5. https://www.phe.gov/s3/dualuse/Documents/p3co.pdf

6. https://www.fda.gov/media/135020/download#:~:text=in%20the%20vaccine.-,AUDENZ%20is%20approved%20for%20use%20in%20persons%206%20months%20of,subtype%20contained%20in%20the%20vaccine.&text=Administer%20two%20doses%20of%20AUDENZ,each)%2C%2021%20days%20apart.

7. https://www.cslseqirus.us/news/csl-seqirus-us-government-award-to-manufacture-and-assess-influenza-a-h5n8-pre-pandemic-vaccine

8. https://www.technologyreview.com/2021/02/14/1018296/bill-gates-climate-change-beef-trees-microsoft/

9. https://www.weforum.org/agenda/2019/06/you-will-be-eating-replacement-meats-within-20-years-heres-why/

10. https://www.weforum.org/agenda/2020/06/the-great-reset-this-weeks-world-vs-virus-podcast/

11. Innovating to zero! | Bill Gates

12. https://www.sciencedirect.com/science/article/pii/S1477893923000984

Featured image is from The Organic Prepper

Articles by: Dr. Peter McCullough and Nicolas Hulscher